ArticleFrontiers in oncology2024

A phase III study to access the safety and efficacy of prolgolimab 250 mg fixed dose administered every 3 weeks versus prolgolimab 1 mg/kg every 2 weeks in patients with metastatic melanoma (FLAT).

Lev Demidov et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.